Thanks Birdman. Appreciate you sharing that. It does look like investors are thinking “oh no, EPS is coming back to $1.80 in 22/23 once the covid turbocharge is gone, let’s get out”. But as Chella observes, even that diminished EPS still looks fine relative to current share price. My understanding is that the base business will continue to steadily grow. I’m assuming the 6% forecast reduction in Australian pathology in 22/23 relates to the covid bonus subsiding. With the buyback continuing (supporting EPS going forward) and some prospects for further buybacks and/or acquisitions, a share price in the mid 30’s for such a quality company seems like a “buy” to me.
Why is Share Price Falling?, page-23
-
- There are more pages in this discussion • 8 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add SHL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$27.18 |
Change
-0.180(0.66%) |
Mkt cap ! $13.05B | |||
| Open | High | Low | Value | Volume |
| $27.22 | $27.33 | $27.06 | $15.03M | 553.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1587 | $27.15 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $27.19 | 8827 | 4 |
View Market Depth
| Last trade - 16.10pm 11/10/2024 (20 minute delay) ? |
| SHL (ASX) Chart |